Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer ; volume:150 ; number:2 ; day:8 ; month:2 ; year:2024 ; pages:1-8 ; date:2.2024
Journal of cancer research and clinical oncology ; 150, Heft 2 (8.2.2024), 1-8, 2.2024
- Creator
-
Peres, Tobias
Aeppli, Stefanie
Fischer, Stefanie
Gysel, Katrin
Rothermundt, Christian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-023-05525-0
- URN
-
urn:nbn:de:101:1-2405232107428.389136501865
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 8:44 AM UTC
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Peres, Tobias
- Aeppli, Stefanie
- Fischer, Stefanie
- Gysel, Katrin
- Rothermundt, Christian
- SpringerLink (Online service)
Other Objects (12)
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Disseminated Carcinomatosis of the Bone Marrow from Castration-Resistant Prostate Cancer Revealed by Choline Positron Emission Tomography-Computed Tomography
Osteoclasts directly influence castration-resistant prostate cancer cells
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Disseminated Carcinomatosis of the Bone Marrow from Castration-Resistant Prostate Cancer Revealed by Choline Positron Emission Tomography-Computed Tomography
Osteoclasts directly influence castration-resistant prostate cancer cells
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Disseminated Carcinomatosis of the Bone Marrow from Castration-Resistant Prostate Cancer Revealed by Choline Positron Emission Tomography-Computed Tomography
Osteoclasts directly influence castration-resistant prostate cancer cells
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment